Annexin V-iFluor 647 Apoptosis Detection Kit

Product details

Annexin V-iFluor 647 Apoptosis Detection Kit (ab219919) contains Annexin V labeled with our proprietary orange fluorescent dye iFluor 647, which allows the identification and quantification of apoptotic cells on a single-cell basis by flow cytometry or fluorescence microscopy.

The iFluor 647 dye (Ex/Em = 650/680 nm) has spectral properties almost identical to those of Cy5^® or Alexa Fluor^® 647, making it convenient to be used for common fluorescence instruments equipped with the light sources and filters for Cy5^® or Alexa Fluor^® 647.

Annexins are a family of calcium-dependent phospholipid-binding proteins. They are abundant in eukaryotic organisms belonging to a family of ubiquitous

Apoptosis is a regulated process of cell death that occurs during embryonic development as well as maintenance of tissue homeostasis. Inappropriately regulated apoptosis is implicated in different disease states, such as neurodegeneration disease and cancer. The apoptosis program is characterized by morphologic features, including loss of plasma membrane asymmetry and attachment, condensation off the cytoplasm and nucleus, and compaction and fragmentation of the nuclear chromatin. Exposure of phosphatidylserine (PS) on the external surface of the cell membrane has been reported to occur in the early phases of apoptotic cell death, during which the cell membrane remains intact. In leukocyte apoptosis, PS on the outer surface of the cell marks the cell for recognition and phagocytosis by macrophages. The human vascular anticoagulant, annexin V, is a 35-36 kDa Ca²⁺ dependent phospholipid binding protein that has a high affinity for PS, and shows minimal binding to phosphatidylcholine and sphingomyelin. Changes in PS asymmetry, which can be analyzed by measuring annexin V binding to the cell membrane, are generally observed before morphological changes associated with apoptosis occurred and before membrane integrity is lost.

Cy5^® and Alexa Fluor^® 647 are the trademarks of GE Healthcare and Invitrogen respectively.